MOLN
Molecular Partners AG
NASDAQ · Healthcare · Biotechnology · CH
$4.11
−5.52%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | 5.0M | 7.0M | 189.6M |
| Cost of Revenue | 11.2M | 2.0M | 47.5M | 47.8M | 50.7M |
| Gross Profit | (11.2M) | (2.0M) | (42.5M) | (40.8M) | 138.8M |
| Operating Expenses | |||||
| R&D Expense | 31.4M | 40.2M | 48.6M | 48.8M | 50.7M |
| SG&A Expense | 15.6M | 14.9M | 17.2M | 19.0M | 21.8M |
| General & Admin Expense | — | 14.9M | 17.2M | 19.0M | 21.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (185.5K) | (4.2M) | (47.1M) | (47.5M) | 372.0K |
| Total Operating Expenses | 46.8M | 50.9M | 18.7M | 20.3M | 72.9M |
| Cost and Expenses | 58.0M | 58.1M | 66.2M | 68.1M | 72.9M |
| Operating Income (EBIT) | (57.7M) | (58.1M) | (61.2M) | (61.1M) | 116.6M |
| Non-Operating | |||||
| Interest Income | 967.9K | 1.5M | 3.4M | 4.3M | 1.2M |
| Interest Expense | 40.7K | 18.0K | 25.0K | 49.0K | 648.1K |
| Net Interest Income | 927.2K | 1.5M | 3.3M | 4.2M | 547.6K |
| Other Non-Op Income/Expense | 472.6K | (3.5M) | 7.2M | (876.0K) | 1.2M |
| Non-Operating Income (excl Interest) | (501.0K) | 3.5M | (7.2M) | 842.0K | (1.8M) |
| EBT (Pre-Tax Income) | (57.3M) | (61.6M) | (54.0M) | (62.0M) | 117.9M |
| Income Tax Expense | 5.0K | 2.0K | 2.0K | — | — |
| Bottom Line | |||||
| Net Income | (57.5M) | (61.7M) | (54.0M) | (62.0M) | 117.9M |
| Earnings from Cont. Ops | (57.5M) | (61.7M) | (54.0M) | (62.0M) | 117.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (57.5M) | (61.7M) | (54.0M) | (62.0M) | 117.9M |
| Per Share | |||||
| Basic EPS | ($1.35) | ($1.65) | ($1.59) | ($1.89) | $3.63 |
| Diluted EPS | ($1.35) | ($1.65) | ($1.59) | ($1.89) | $3.54 |
| Revenue Per Share | $0.00 | $0.00 | $0.15 | $0.21 | $5.84 |
| Shares | |||||
| Basic Shares Outstanding | 38.8M | 37.3M | 34.0M | 32.8M | 32.5M |
| Diluted Shares Outstanding | 38.8M | 37.3M | 34.0M | 32.8M | 33.3M |
| Profitability Metrics | |||||
| EBITDA | (55.4M) | (59.5M) | (51.6M) | (59.5M) | 119.0M |
| D&A | 2.3M | 2.1M | 2.4M | 2.4M | 2.4M |
| EBIT | (57.7M) | (61.6M) | (54.0M) | (62.0M) | 116.6M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026